130 related articles for article (PubMed ID: 34635981)
1. FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population.
Li B; Cheng X; Zhu Y; Wan H; Lu Z; Cai Y; Li W; Yi P; Liu L; Chang J; Miao X; Tian J; Zhong R
Breast Cancer; 2022 Mar; 29(2):247-259. PubMed ID: 34635981
[TBL] [Abstract][Full Text] [Related]
2. Integrative functional genomics identifies regulatory genetic variant modulating RAB31 expression and altering susceptibility to breast cancer.
Zhang Y; Yang B; Cheng X; Liu L; Zhu Y; Gong Y; Yang Y; Tian J; Peng X; Zou D; Yang L; Mei S; Wang X; Lou J; Ke J; Li J; Gong J; Chang J; Yuan P; Zhong R
Mol Carcinog; 2018 Dec; 57(12):1845-1854. PubMed ID: 30182384
[TBL] [Abstract][Full Text] [Related]
3. A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population.
Zhang Y; Li Y; Jiang S; Chen W; Lou J; Ke J; Li J; Zhu Y; Gong Y; Yang Y; Tian J; Peng X; Zou D; Gong J; Chang J; Miao X; Zhong R
Oncotarget; 2016 Dec; 7(49):81691-81697. PubMed ID: 27835577
[TBL] [Abstract][Full Text] [Related]
4. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
5. Trans-acting non-synonymous variant of FOXA1 predisposes to hepatocellular carcinoma through modulating FOXA1-ERα transcriptional program and may have undergone natural selection.
Wang S; Xiang C; Mou L; Yang Y; Zhong R; Wang L; Sun C; Qin Z; Yang J; Qian J; Zhao Y; Wang Y; Pan X; Qie J; Jiang Y; Wang X; Yang Y; Zhou WP; Miao X; He F; Jin L; Wang H
Carcinogenesis; 2020 Apr; 41(2):146-158. PubMed ID: 31400761
[TBL] [Abstract][Full Text] [Related]
6. Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
Meyer KB; O'Reilly M; Michailidou K; Carlebur S; Edwards SL; French JD; Prathalingham R; Dennis J; Bolla MK; Wang Q; de Santiago I; Hopper JL; Tsimiklis H; Apicella C; Southey MC; Schmidt MK; Broeks A; Van 't Veer LJ; Hogervorst FB; Muir K; Lophatananon A; Stewart-Brown S; Siriwanarangsan P; Fasching PA; Lux MP; Ekici AB; Beckmann MW; Peto J; Dos Santos Silva I; Fletcher O; Johnson N; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Guénel P; Truong T; Laurent-Puig P; Menegaux F; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Milne RL; Zamora MP; Arias JI; Benitez J; Neuhausen S; Anton-Culver H; Ziogas A; Dur CC; Brenner H; Müller H; Arndt V; Stegmaier C; Meindl A; Schmutzler RK; Engel C; Ditsch N; Brauch H; Brüning T; Ko YD; ; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Matsuo K; Ito H; Iwata H; Yatabe Y; Dörk T; Helbig S; Bogdanova NV; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Chenevix-Trench G; ; ; Wu AH; Tseng CC; Van Den Berg D; Stram DO; Lambrechts D; Thienpont B; Christiaens MR; Smeets A; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Radice P; Peterlongo P; Bonanni B; Bernard L; Couch FJ; Olson JE; Wang X; Purrington K; Giles GG; Severi G; Baglietto L; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Simard J; Goldberg MS; Labrèche F; Dumont M; Teo SH; Yip CH; Phuah SY; Kristensen V; Grenaker Alnæs G; Børresen-Dale AL; Zheng W; Deming-Halverson S; Shrubsole M; Long J; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Kauppila S; Andrulis IL; Knight JA; Glendon G; Tchatchou S; Devilee P; Tollenaar RA; Seynaeve CM; García-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson K; Hooning MJ; Martens JW; van den Ouweland AM; van Deurzen CH; Hall P; Li J; Liu J; Humphreys K; Shu XO; Lu W; Gao YT; Cai H; Cox A; Reed MW; Blot W; Signorello LB; Cai Q; Pharoah PD; Ghoussaini M; Harrington P; Tyrer J; Kang D; Choi JY; Park SK; Noh DY; Hartman M; Hui M; Lim WY; Buhari SA; Hamann U; Försti A; Rüdiger T; Ulmer HU; Jakubowska A; Lubinski J; Jaworska K; Durda K; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Vachon C; Slager S; Fostira F; Pilarski R; Shen CY; Hsiung CN; Wu PE; Hou MF; Swerdlow A; Ashworth A; Orr N; Schoemaker MJ; Ponder BA; Dunning AM; Easton DF
Am J Hum Genet; 2013 Dec; 93(6):1046-60. PubMed ID: 24290378
[TBL] [Abstract][Full Text] [Related]
7. Genetic variations of DNA bindings of FOXA1 and co-factors in breast cancer susceptibility.
Wen W; Chen Z; Bao J; Long Q; Shu XO; Zheng W; Guo X
Nat Commun; 2021 Sep; 12(1):5318. PubMed ID: 34518541
[TBL] [Abstract][Full Text] [Related]
8. Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.
Zhou S; Hawley JR; Soares F; Grillo G; Teng M; Madani Tonekaboni SA; Hua JT; Kron KJ; Mazrooei P; Ahmed M; Arlidge C; Yun HY; Livingstone J; Huang V; Yamaguchi TN; Espiritu SMG; Zhu Y; Severson TM; Murison A; Cameron S; Zwart W; van der Kwast T; Pugh TJ; Fraser M; Boutros PC; Bristow RG; He HH; Lupien M
Nat Commun; 2020 Jan; 11(1):441. PubMed ID: 31974375
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing.
Robbez-Masson LJ; Bödör C; Jones JL; Hurst HC; Fitzgibbon J; Hart IR; Grose RP
PLoS One; 2013; 8(11):e78839. PubMed ID: 24265722
[TBL] [Abstract][Full Text] [Related]
10. Identification of a regulatory variant that binds FOXA1 and FOXA2 at the CDC123/CAMK1D type 2 diabetes GWAS locus.
Fogarty MP; Cannon ME; Vadlamudi S; Gaulton KJ; Mohlke KL
PLoS Genet; 2014 Sep; 10(9):e1004633. PubMed ID: 25211022
[TBL] [Abstract][Full Text] [Related]
11. The transcriptional regulation of SOX2 on FOXA1 gene and its application in diagnosis of human breast and lung cancers.
Li X; Chen S; Sun T; Xu Y; Chen Y; Liu Y; Xiang R; Li N
Clin Lab; 2014; 60(6):909-18. PubMed ID: 25016694
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
14. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
15. Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.
Droog M; Nevedomskaya E; Kim Y; Severson T; Flach KD; Opdam M; Schuurman K; Gradowska P; Hauptmann M; Dackus G; Hollema H; Mourits M; Nederlof P; van Boven H; Linn SC; Wessels L; van Leeuwen FE; Zwart W
Cancer Res; 2016 Jul; 76(13):3773-84. PubMed ID: 27197147
[TBL] [Abstract][Full Text] [Related]
16. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function.
Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J
Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
Yamaguchi N; Nakayama Y; Yamaguchi N
J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
[TBL] [Abstract][Full Text] [Related]
18. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee JY; Park YJ; Oh N; Kwack KB; Park KS
Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis through repression of FOXA1.
Huang JZ; Chen M; Zeng M; Xu SH; Zou FY; Chen D; Yan GR
J Pathol; 2016 Jun; 239(2):186-96. PubMed ID: 26969828
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 defines cancer cell specificity.
Zhang G; Zhao Y; Liu Y; Kao LP; Wang X; Skerry B; Li Z
Sci Adv; 2016 Mar; 2(3):e1501473. PubMed ID: 27034986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
